None listed
Conditions
Interventions
Intervention1: 1 Baby massage oil
2 Baby moisturizing soap that is jasmine fragrance
3 Baby gentle body wash and shampoo
4 Baby nourishing cream with chamomile extract
5 Baby diaper rash cream that is
Sponsors
Azafran Innovacion Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1) Age: 18-65 years (both inclusive) at the time of consent. 2) Sex: Males and non-pregnant/non-lactating females (preferably equal numbers of males and females). 3) Females of childbearing potential must have a negative urine pregnancy test performed on Day 01 prior to patch application. 4) Subjects who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results. 5) Subjects are in good general health as determined by the Investigator on the basis of medical history. 6) Subjects willing and able to follow the study directions, to participate in the study, returning for all specified visits. 7) Subjects must be able to understand and provide written informed consent to participate in the study. 8) Subjects willing to shower using the same soap/cleansers between Screening and End of the Study. 9) Subjects willing to refrain from vigorous physical exercise during the study period.
Exclusion criteria
Exclusion criteria: 1) Subject is pregnant or lactating. 2) Subjects having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading. 3) Medication which may affect skin response and/or past medical history. 4) Subjects having history of diabetes. 5) Subjects have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months. 6) Subjects suffering from any active clinically significant skin diseases which may contraindicate. 7) Subjects having history of any skin diseases including eczema, atopic dermatitis or active cancer. 8) Participation in any patch test for irritation or sensitization within the last four weeks. 9) Subjects having history of asthma or COPD (Chronic obstructive pulmonary disease). 10) Subjects with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous. 11) Individual who has a medical condition or is taking or has taken a medication which, in the Investigatorâ??s judgment, makes the subject ineligible or places the subject at undue risk. 12) Subject with known allergy or sensitization to medical adhesives, bandages. 13) Subjects have participation in a clinical drug study or skin irritation/sensitization study during the 30 days preceding the initial patch application in this study. 14) Subject reports a history of skin sensitivity to shampoos and detergents or a known hypersensitivity and/or sensitization to medical adhesives. 15) Subjects reports use of systemic or topical antihistamines (at any site) or uses of topical drugs at patch site(s) within 72 hours prior to patch application. 16) Participation in other patches study simultaneously. 17) Use of any: i. Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application. ii. Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of Test Product application (steroidal nose drops and/or eye drops are permitted). iv. Topical drugs used at application site.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 To determine the cumulative irritation potential of the test product 2 To determine sensitization potential of the product.Timepoint: 1 Induction Phase: Visit 3, Visit 4, Visit 5, Visit 6, Visit 7, Visit 8, Visit 9, Visit 10 and Visit 11. 2 Induction Phase: Visit 3, Visit 4, Visit 5, Visit 6, Visit 7, Visit 8, Visit 9, Visit 10 and Visit 11. Challenge Phase: Visit 14, Visit 15, visit 16 and Visit 17. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not ApplicableTimepoint: Not Applicable | — |
Countries
India
Contacts
Public ContactMs Maheshvari Patel
Cliantha Research
Outcome results
None listed